Apimeds Pharmaceuticals US Inc
APUS
查看詳細走勢圖
1.620USD
+0.200+13.70%
收盤 02/06, 16:00（美東）報價延遲15分鐘
20.37M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+13.70%
5天
-12.43%
1月
-6.90%
6月
+3.18%
今年開始到現在
-1.22%
1年
0.00%
查看詳細走勢圖
TradingKey 股票評分
由於缺少必要的數據，暫時無法對該公司進行評分
Apimeds Pharmaceuticals US Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Apimeds Pharmaceuticals US Inc簡介
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
公司代碼APUS
公司Apimeds Pharmaceuticals US Inc
CEOMenon (Vin)
網址https://www.apimedsus.com/
相關品種
+3.63%
+3.17%
+0.93%
+1.99%
+1.78%
+1.53%
-0.96%
+4.49%
+2.10%
+10.00%
+2.72%
+4.07%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%熱門品種
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
70875.010
+1273.830 (+1.83%)
282.580
+22.390 (+8.61%)
2134.120
+31.300 (+1.49%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
